The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
Site Search
Showing 1 - 5 of 5 results
News
|
Jan. 4, 2022
|
2 min read
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
News
|
Jan. 6, 2022
|
1 min read
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
News
|
Jan. 28, 2022
|
7 min read
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
News
|
March 7, 2024
|
2 min read
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
News
|
March 18, 2024
|
2 min read